Easton Pharmaceutica Stock Z Score
EAPH Stock | USD 0.0001 0.00 0.00% |
Easton | Z Score |
Easton Pharmaceutica Company Z Score Analysis
Easton Pharmaceutica's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Easton Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Easton Pharmaceutica is extremely important. It helps to project a fair market value of Easton Stock properly, considering its historical fundamentals such as Z Score. Since Easton Pharmaceutica's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Easton Pharmaceutica's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Easton Pharmaceutica's interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
Competition |
According to the company's disclosures, Easton Pharmaceutica has a Z Score of 0.0. This is 100.0% lower than that of the Pharmaceuticals sector and about the same as Health Care (which currently averages 0.0) industry. The z score for all United States stocks is 100.0% higher than that of the company.
Easton Pharmaceutica Current Valuation Drivers
We derive many important indicators used in calculating different scores of Easton Pharmaceutica from analyzing Easton Pharmaceutica's financial statements. These drivers represent accounts that assess Easton Pharmaceutica's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Easton Pharmaceutica's important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 28.0M | 10.4M | 1.3M | 807.0K | 726.3K | 690.0K | |
Enterprise Value | 30.2M | 12.5M | 9.6M | 3.3M | 3.0M | 2.8M |
Easton Fundamentals
Return On Equity | -0.0269 | ||||
Return On Asset | -0.0083 | ||||
Current Valuation | 2.14 M | ||||
Shares Outstanding | 1.34 B | ||||
Price To Earning | (22.00) X | ||||
Price To Book | 0 X | ||||
Price To Sales | 0.06 X | ||||
Gross Profit | 201.4 K | ||||
EBITDA | (188.54 K) | ||||
Net Income | (188.54 K) | ||||
Cash And Equivalents | 5.81 K | ||||
Total Debt | 3.28 M | ||||
Debt To Equity | 0.43 % | ||||
Current Ratio | 0.69 X | ||||
Book Value Per Share | 0.01 X | ||||
Cash Flow From Operations | (188.54 K) | ||||
Beta | 15.58 | ||||
Market Capitalization | 134.49 K | ||||
Total Asset | 10.19 M | ||||
Retained Earnings | (39.82 M) | ||||
Working Capital | (194.5 K) | ||||
Current Asset | 297 K | ||||
Current Liabilities | 137 K | ||||
Net Asset | 10.19 M |
About Easton Pharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Easton Pharmaceutica's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Easton Pharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Easton Pharmaceutica based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Easton Pharmaceutica offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Easton Pharmaceutica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Easton Pharmaceutica Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Easton Pharmaceutica Stock:Check out Easton Pharmaceutica Piotroski F Score and Easton Pharmaceutica Valuation analysis. For more detail on how to invest in Easton Stock please use our How to Invest in Easton Pharmaceutica guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Easton Pharmaceutica. If investors know Easton will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Easton Pharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share 0.001 | Return On Assets (0.01) | Return On Equity (0.03) |
The market value of Easton Pharmaceutica is measured differently than its book value, which is the value of Easton that is recorded on the company's balance sheet. Investors also form their own opinion of Easton Pharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is Easton Pharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Easton Pharmaceutica's market value can be influenced by many factors that don't directly affect Easton Pharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Easton Pharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if Easton Pharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Easton Pharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.